First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)

NCT05749900 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

44

Enrollment

OTHER

Sponsor class

Conditions

HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer

Interventions

DRUG: Trastuzumab+Nivolumab+Gemcitabine+Cisplatin

Sponsor

Yonsei University